Co-Authors
This is a "connection" page, showing publications co-authored by JAMES C YAO and DAVID FOGELMAN.
Connection Strength
0.386
-
Assessment of Clinical Response Following Atezolizumab and Bevacizumab Treatment in Patients With Neuroendocrine Tumors: A Nonrandomized Clinical Trial. JAMA Oncol. 2022 06 01; 8(6):904-909.
Score: 0.219
-
Perfusion computed tomography as functional biomarker in randomized run-in study of bevacizumab and everolimus in well-differentiated neuroendocrine tumors. Pancreas. 2015 Mar; 44(2):190-7.
Score: 0.133
-
Pazopanib and depot octreotide in advanced, well-differentiated neuroendocrine tumours: a multicentre, single-group, phase 2 study. Lancet Oncol. 2015 Jun; 16(6):695-703.
Score: 0.034